AADI aadibio.com: Enterprise Value to EBITDA Ratio

Corporate company logo of Aadi Bioscience, Inc. (AADI)

Aadi Bioscience (AADI) develops targeted drugs to combat tumors. This chart illustrating the price evolution confirms the impact of Fyarro sales on margins, with EV/EBITDA standing at . The company minimizes costs by outsourcing drug synthesis and testing to external contractors. Due to the humanitarian status of the medicine, the business is shielded from sanctions and global political upheavals, maintaining operational resilience.

AADI (Aadi Bioscience, Inc.) Enterprise Value to Operating Income Before Depreciation Ratio history from 07/04/2022 to 11/10/2026

Comprehensive metric breakdowns and analytics for aadibio.com (AADI)

- stock price and consensus target price:
Stock Quotes Aadi Bioscience, Inc.|AADI - Average Forecast Price
- company stock capitalization data:
Market Valuation AADI|AADI - Value Adjusted for Debt and Cash
- business book valuation details:
Accounting Value per Share Aadi Bioscience|AADI - Total Net Assets|Market Capitalization to Book Value Ratio aadibio.com|AADI - Company Total Assets
- debt and solvency information:
Debt to Equity Aadi Bioscience|AADI - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Aadi Bioscience, Inc.|AADI - Company Total Indebtedness|Debts to Book Capitalization AADI|AADI - Long-Term Debt|Company Current Liabilities Aadi Bioscience|Quick Ratio aadibio.com
- net income and valuation multiples indicators:
AADI - Company Net Income|Projected Future Earnings Aadi Bioscience|AADI - Price to Earnings Multiple|Projected Price to Earnings Aadi Bioscience, Inc.|AADI - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio AADI|AADI - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Aadi Bioscience|AADI - Earnings per share for the trailing year|Quarterly EPS earnings growth aadibio.com|AADI - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Aadi Bioscience
Basic company analysis:Aadi Bio AADI
Original product of aadibio.com

This multiple relates the total enterprise value, including debt, to its operating profit before taxes and depreciation and amortization. This metric determines the real value of the asset by excluding the impact of debt load and the tax regime. Analyzing the business valuation of Aadi Bioscience (AADI) through EV/EBITDA trends is critically important, as high R&D costs and strict FDA oversight impact capitalization.

Competitor analysis

Genmab US - Enterprise Value to EBITDA Ratio|Exelixis Inc. (EXEL) - Company Value to EBITDA|NUVL: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation KYMR (kymeratx.com)|IDYA (IDEAYA Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|ELVN: Enterprise Value to Operating Income Before Depreciation Ratio|ORIC (ORIC Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Relay Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nurix Therapeutics (NRIX)|TYRA (tyra.bio) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple VSTM (Verastem)|Enterprise Value to EBITDA Multiple Monte Rosa Therapeutics Inc|Cullinan Therapeutics Inc - EV/EBITDA Multiple|Company Value to EBITDA Immuneering Corp.|CCCC (C4 Therapeutics, Inc.) - Enterprise Value to EBITDA Ratio|BDTX: Enterprise Value to Operating Income Before Depreciation Ratio|RPTX (Repare Therapeutics Inc.) - EV/EBITDA Multiple|Company Value to EBITDA PMV Pharmaceuticals Inc. PMVP|EV/EBITDA Multiple KPTI|propanc.com - Enterprise Value to Operating Income Before Depreciation|Bio Green Med Solution Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ALRN|BPMC: Enterprise Value to EBITDA Ratio|GlycoMimetics, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|SWTX: EV/EBITDA Multiple